APH Stock Overview
Acquires, markets, and distributes consumer healthcare products and prescription medicines in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Alliance Pharma plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.37 |
| 52 Week High | UK£0.53 |
| 52 Week Low | UK£0.25 |
| Beta | 0.64 |
| 11 Month Change | -3.87% |
| 3 Month Change | -1.32% |
| 1 Year Change | -23.96% |
| 33 Year Change | -63.29% |
| 5 Year Change | -44.82% |
| Change since IPO | 86.50% |
Recent News & Updates
Recent updates
Is Alliance Pharma (LON:APH) A Risky Investment?
Jun 21
Not Many Are Piling Into Alliance Pharma plc (LON:APH) Just Yet
Feb 23Estimating The Intrinsic Value Of Alliance Pharma plc (LON:APH)
Nov 21We Think Alliance Pharma (LON:APH) Is Taking Some Risk With Its Debt
May 26Alliance Pharma plc Just Missed Earnings - But Analysts Have Updated Their Models
Mar 24We Think Alliance Pharma (LON:APH) Can Stay On Top Of Its Debt
Sep 30An Intrinsic Calculation For Alliance Pharma plc (LON:APH) Suggests It's 41% Undervalued
May 28Alliance Pharma (LON:APH) Has A Pretty Healthy Balance Sheet
Mar 30Did Alliance Pharma's (LON:APH) Share Price Deserve to Gain 81%?
Dec 24Do Fundamentals Have Any Role To Play In Driving Alliance Pharma plc's (LON:APH) Stock Up Recently?
Nov 19
Shareholder Returns
| APH | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -6.0% | -4.2% | -1.5% |
| 1Y | -24.0% | 12.7% | 5.8% |
Return vs Industry: APH underperformed the UK Pharmaceuticals industry which returned 16.2% over the past year.
Return vs Market: APH underperformed the UK Market which returned 6.3% over the past year.
Price Volatility
| APH volatility | |
|---|---|
| APH Average Weekly Movement | 8.3% |
| Pharmaceuticals Industry Average Movement | 7.7% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.8% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: APH has not had significant price volatility in the past 3 months.
Volatility Over Time: APH's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 292 | Nick Sedgwick | www.alliancepharmaceuticals.com |
Alliance Pharma plc acquires, markets, and distributes consumer healthcare products and prescription medicines in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. It provides its products under the Aloclair, Anbesol, Asthon & Parsons, Forceval, Hydromol, Kelo-Cote, MacuShield, Vamousse, Nizoral, and Amberen brand names. The company was incorporated in 1996 and is headquartered in Chippenham, the United Kingdom.
Alliance Pharma plc Fundamentals Summary
| APH fundamental statistics | |
|---|---|
| Market cap | UK£203.52m |
| Earnings (TTM) | -UK£33.14m |
| Revenue (TTM) | UK£180.68m |
1.1x
P/S Ratio-6.1x
P/E RatioIs APH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APH income statement (TTM) | |
|---|---|
| Revenue | UK£180.68m |
| Cost of Revenue | UK£75.66m |
| Gross Profit | UK£105.02m |
| Other Expenses | UK£138.16m |
| Earnings | -UK£33.14m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.061 |
| Gross Margin | 58.12% |
| Net Profit Margin | -18.34% |
| Debt/Equity Ratio | 52.2% |
How did APH perform over the long term?
See historical performance and comparison